Effect of Anlotinib Combined with Compound Banmao Capsules in the Treatment of Chemotherapy Intolerance and Driver Gene Negative of Advanced NSCLC Complicated with COPD
Objective:To investigate the effect of Anlotinib combined with Compound Banmao Capsules in the treatment of chemotherapy intolerance and driver gene negative of advanced non-small cell lung cancer(NSCLC)complicated with chronic obstructive pulmonary diseases(COPD).Method:A total of 48 patients with chemotherapy intolerance and driver gene negative of advanced NSCLC complicated with COPD treated in First People's Hospital of Fuzhou from October 2021 to December 2022 were selected and divided into experimental group and control group according to random number table method,with 24 cases in each group.The control group was treated with Compound Banmao Capsules,and the experimental group was treated with Anlotinib on the basis of the control group,both groups were treated for 2 courses.The short-term effect,cell growth related factors[vascular endothelial growth factor(VEGF),matrix metalloproteinase-9(MMP-9)],tumor markers[squamous cell carcinoma antigen(SCCA),carcinoembryonic antigen(CEA),cytokeratin 19 fragment(Cyfra21-1)],quality of life and occurrence of adverse reactions were compared between the two groups.Result:The disease control rate of experimental group was higher than that of control group,the levels of VEGF,MMP-9,SCCA,CEA and Cyfra21-1 of experimental group after treatment were lower than those of control group,and the quality of life of experimental group was better than that of control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Anlotinib combined with Compound Banmao Capsules has high safety in the treatment of chemotherapy intolerance and driver gene negative of advanced NSCLC complicated with COPD,and can reduce the level of tumor markers,improve the quality of life and enhance the therapeutic effect.
万方数据
维普
